NANOBODIES MARKET ANALYSIS

Leading Companies

Global Nanobodies Market: Key Developments

• On February 21 2023, Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a global biotechnology company, announced the launch of the “Nano 100 Project” that aims to develop fully human nanobody drugs for over 100 targets. The project combines the company’s proprietary fully human nanobody mouse named RenNano with its high-throughput in vitro and in vivo antibody screening platforms to develop fully human nanobody drugs on a large-scale.
• In February 2021, i2O Therapeutics, a developer of a platform for oral delivery of traditionally injectable biological drugs, announced a research collaboration with Sanofi to investigate the oral delivery of Sanofi's Nanobody-based medicines that are currently administered through intravenous or subcutaneous injections.
• In August 2020, Numab Therapeutics, a biopharmaceutical company, announced the initiation of a clinical trial to study the safety and immunogenicity of NM21-1480 in adult patients with advanced solid tumors to determine the maximal tolerated dose. This is currently in Phase ½ of clinical trial. NM21-1480 consists of three monovalent antibodies. It is a next-generation multi-specific cancer therapeutic that simultaneously targets the tumor-immunity suppressive PD(L)-1 pathway and the tumor-immunity stimulatory 4-1BB/CD137 pathway.
• In December 2022, Taisho Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, announced the launch of Nanozora (Ozoralizumab) 30 mg syringes for subcutaneous injection, which were included in the National Health Insurance Drug Price List in November 2022.

Global Nanobodies Market - Key Players

Major players operating in the global nanobodies market include Merck KGaA, Sanofi, AlpalifeB Inc, GenScript, Novartis International AG, Taisho Pharmaceutical Holdings Co., Ltd., Sino Biological, Inc., GeneMedi, Biocytogen, Abnova Corporation, NanoTag Biotechnologies, Avillion LLP, Capra Science, Numab Therapeutics, CUSABIO TECHNOLOGY LLC, Proteintech Group, Inc., GT Biopharma, Inc., Confo Therapeutics, R&D Systems, Inc., and Abcepta Biotech Ltd. Co.